Paul Rhodes, PhD
Co-Founder & Chief Executive Officer (CEO)
Dr. Rhodes defines the vision for Specific’s novel and important applications, and leads the identification and development of the company’s most important collaborative clinical relationships. Dr. Rhodes also established Specific’s first overseas office in the BioData Innovation Centre on the grounds of the Wellcome Trust Genome Campus, which houses the Sanger Institute.
Prior to Specific, Dr. Rhodes founded Evolved Machines, where he was PI for the DARPA RealNose program, directing a team of 8 universities and corporations to deliver an end-to-end artificial olfaction device capable of canine-competitive sensitivity in real-world conditions, which fostered development of Specific’s fundamental technology, which can be considered a form of artificial olfaction. During this project Dr. Rhodes oversaw the successful development of the first integrated nanotube FET sensor array, along with advances in the engineering of the Suslick sensor that is the heart of the Specific’s products. Dr. Rhodes’ received an AB in Physics magna cum laude from Harvard University, an MS in Physics from Stanford University, and a PhD in Neuroscience from NYU Medical School.
Chief Financial Officer (CFO)
Mr. Ek joined Specific Dx in August 2021 with over 20 years of public and private corporate financial leadership experience in diagnostics and life sciences. Prior to joining Specific Dx, Mr. Ek served as the Chief Financial Officer of GenMark Diagnostics, a publicly traded rapid molecular diagnostics provider where he oversaw the rapid growth and eventual sale to Roche Diagnostics for $1.8B in early 2021. Prior to GenMark, Mr. Ek held the role of Vice President and International Controller at Affymetrix following its acquisition of eBioscience where he served as VP of Finance and was instrumental in the sale to Affy. He began his career with the accounting firm of Ernst and Young, in the audit and advisory practice where he supported the successful initial public offerings of several San Diego life science firms.
Mr. Ek holds a B.S. in finance from Brigham Young University, a Masters in Accountancy from the University of Notre Dame’s Mendoza College of Business, and is a CPA.
Co-Founder & Chief Operations Officer (COO)
Mr. Martino is COO and a co-founder of Specific Diagnostics. Mr. Martino has contributed in both technical and business capacities as Specific moved from research through product development to commercial stage.
Previously Mr. Martino was General Manager of the mobile and wireless business at Symbol Technologies where he held various roles as the company grew from under $20M in sales to over $2B before being acquired by Motorola in 2007 for nearly $4B, after which Mr. Martino was CTO of Motorola’s enterprise business.
Mr. Martino brings a track record of successful business and technology development. As a General Manager, Mr. Martino led a +$500 M technology business, as CTO and Engineering VP Mr. Martino led complex software and hardware product development. Prior to Specific Tech, Mr. Martino was CTO at Motorola Inc., Enterprise Business where he led development of new products, technology and new businesses. Prior to Motorola Mr. Martino was with Symbol Technologies for nearly 20 years as Symbol grew from $20M in sales to over $2B before being acquired by Motorola in 2007 for nearly $4B. Mr. Martino has a long track record of business success based on engineering and producing successful innovative products. As a pioneer of WiFi, Mr. Martino’s team was the first to ship WiFi products. Mr. Martino’s development record includes many first in the world category creating products including: the world’s first mobile computer with WiFi , world’s first WiFi network infrastructure switch and the world’s first wearable mobile computing system.
Chief Commercial Officer (CCO)
Mr. Bazarko has served as Chief Commercial Officer of Specific Diagnostics since October of 2020. Prior to joining Specific Dx he most recently held the position of Vice President, Commercial Development for the Americas and the General Manager of Canada at Danaher Corporation’s subsidiary Leica Biosystems. Mr. Bazarko Joined Leica as the Vice President of Sales in 2016.
Prior to Danaher, Mr. Bazarko held the positions of Senior Director, Strategic Affairs for North America and Senior Director of the Commercial Sales and Marketing for Life Science division at Roche Diagnostics Corporation. Mr. Bazarko also served in various leadership roles at Life Technologies and Fisher Scientific International. Mr. Bazarko holds a B.S. in Biology from Indiana University and his M.B.A from Northwestern’s Kellogg School of Management.